Abnormal blood pressure patterns during sleep and overall high blood pressure may independently predict cardiovascular disease in patients with juvenile-onset systemic lupus erythematosus(JSLE), according to a recent update on research supported by the Lupus Foundation of America.
Researchers identify key mechanism linked to neuropsychiatric lupus
A breakthrough study by a SUNY Downstate Health Sciences University research team has identified a specific antibody target implicated in neuropsychiatric symptoms of lupus. These symptoms, including cognitive impairment, mood disorders, seizures, headaches and psychosis, are among the most prevalent manifestations of the disease and occur in as many as 80% of adults and 95% of children with lupus.
Safety of tattoos in patients with systemic lupus erythematosus
Individuals were asked whether they had tattoos or not by the experts in order to ascertain the safety of tattoos in individuals with systemic lupus erythematosus (SLE).
Twenty-eight patients (19%, 26 women, median age 33 (25–42) years, 65 tattoos in total) had ≥1 tattoo.The characteristics of the tattoos and the immediate complications were investigated and compared with those of a matched control group.
Blood Clotting Proteins Discovered as Biomarkers of Lupus Nephritis
Researchers have discovered that blood clotting proteins in urine can act as biomarkers in patients with systemic lupus erythematosus (SLE), especially those with lupus nephritis.
The team of researchers at the University of Houston found that blood clotting proteins, both the ones that promote blood clotting (prothrombic) and those that disperse them (thrombolytic) are elevated in the urine of patients with lupus nephritis (LN).
Pregnant SLE patients discontinue medication when they shouldn't
Marital status and age of SLE diagnosis: the potential for differences related to sex and gender
Risks of Interstitial Cystitis Among Patients with SLE
Minorities in US Experience More Severe SLE Symptoms, Study Says
Lupus Linked to Poor Outcomes Post-Primary Total Hip Arthroplasty
Individuals with systemic lupus erythematosus (SLE) who have primary total hip arthroplasty (THA) are at higher risk for implant infection, discharge to an inpatient facility, more expensive hospital bills, and increased blood transfusions than people without SLE, according to a study recently published in Lupus.
Fracture Risk is High in Lupus
In a study published in a recent issue of Arthritis & Rheumatology, investigators found that patients with lupus nephritis were far more likely to break a bone than patients who do not have lupus.
“Patients with lupus nephritis may be at particularly high risk of fracture due to secondary or tertiary hyperparathyroidism and vitamin D deficiency,” said study author Sara Tedeschi, M.D., MPH, a rheumatology fellow at Brigham and Women’s Hospital.
Pregnancy outcome in women with active and inactive lupus nephritis
Study Shows Gazyva® May Offer Potential New Treatment for Lupus Nephritis
The Lupus Research Alliance shared positive topline results from a Phase 2 clinical study of a potential new treatment for proliferative lupus nephritis, the most severe form of kidney damage caused by lupus. Genentech, a member of the Roche Group, reported that at one year their drug Gazyva® (obinutuzumab) helped more patients achieve a complete response to treatment when added to standard of care with either mycophenolate mofetil or mycophenolic acid plus corticosteroids than those receiving standard of care alone.
How a common viral infection can lead to autoimmunity
Researchers in Dr. Leona Gilbert's research group at the University of Jyväskylä have proposed a novel mechanism for how a common viral infection could lead to an autoimmune disease. Dr. Gilbert's team demonstrated for the first time how viral components triggered cellular and ultimately tissue damage in mice, thus, providing an answer to a missing link between an infection and autoimmunity.
Research Supports Measuring Blood for Hydroxychloroquine Levels
Hydroxychloroquine (Plaquenil®) is the most prescribed medication in the treatment of lupus and has numerous benefits including prevention of flares, prolonged survival, and other positive outcomes. Medication non-adherence is reported in up to 80% of people with lupus and is associated with reduced health outcomes.
Microbiome Composition Influences Autoantibody Development in Lupus
People with lupus produce autoantibodies causing the body to attack itself and promoting inflammation and tissue damage. A new research study divided people with lupus into two cohorts, or groups, so they could identify key differences. One group consisted of first-degree relatives (FDRs) without lupus and healthy people, and their molecular profiles were compared against a second group, which consisted of unrelated people with and without lupus.
Study Finds Link Between Fatty Acid Consumption and Lupus Disease Activity
Lupus Treatments Can Be Tailored to Patient's Individual Cells
The kidneys of patients living with systemic lupus erythematosus (SLE) are often under assault, and not all those living with the disease will respond to standard treatment. A new report published in the journal Nature Immunology online May 20 shows how tissue samples from these patients can accurately predict those more likely than not to respond to therapy. SLE is a disease marked by the attack on joints, skin, and kidneys by the body's immune system..
